Indian drugmaker Hikma has agreed in principle to a $150 million settlement to resolve lawsuits claiming that it contributed to the opioid crisis in the US, which could al
UK-based pharma Hikma has snapped up assets from embattled Insys Therapeutics, including potential generics of Mylan’s Epipen allergic reaction shot and a drug to reverse the effects of opi